James N. Ingle

54.5k citations

365 papers · 23.6k indexed · 10 hit papers · h-index 74

Impact in

Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Bone health and treatments
- Cancer Risks and Factors

Papers in

Cancer Research 162
- Breast Cancer Treatment Studies 129
- Cancer Genomics and Diagnostics 25
Oncology 208
- Cancer Treatment and Pharmacology 72
- HER2/EGFR in Cancer Research 60
- Cancer Risks and Factors 25

Co-authors: Edith A. Perez Silvana Martino Vera J. Suman Matthew P. Goetz Nancy E. Davidson Wilma L. Lingle Hyman B. Muss Dongsheng Tu
Journals: Journal of Clinical Oncology (80 papers)Cancer (37 papers)Breast Cancer Research and Treatment (26 papers)Cancer Research (25 papers)Clinical Cancer Research (20 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

James N. Ingle

358 papers receiving 22.8k citations

Hit Papers

10 papers align trajectories log scale

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy 2018 · 237 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Clinical Pharmacology & Therapeutics
2016 New England Journal of Medicine
2016 Journal of Clinical Oncology
2011 New England Journal of Medicine
2009 Annals of Oncology
2005 JNCI Journal of the National Cancer Institute
2005 Journal of Clinical Oncology
2003 Journal of Clinical Oncology
2003 Journal of Clinical Oncology
2003 Journal of Clinical Oncology

Peers

Countries citing papers authored by James N. Ingle

Since Specialization

Citations

This map shows the geographic impact of James N. Ingle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James N. Ingle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James N. Ingle more than expected).

Fields of papers citing papers by James N. Ingle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James N. Ingle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James N. Ingle. The network helps show where James N. Ingle may publish in the future.

Co-authors

The 25 scholars most cited alongside James N. Ingle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James N. Ingle Line = papers co-authored together James N. Ingle links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer” Journal of Clinical Oncology ·Matthew P. Goetz, Grace M. Choong, Tanya L. Hoskin, Judy C. Boughey, Sameera R. Wijayawardana, James N. Ingle	2025	0
2	Identification of a Notch transcriptomic signature for breast cancer Breast Cancer Research ·Eike-Benjamin Braune, Felix Geist, Xiaojia Tang, Krishna R. Kalari, Judy C. Boughey, Liewei Wang, Roberto A. Leon‐Ferre, Antonino B. D’Assoro, James N. Ingle, Matthew P. Goetz, Julian Kreis, Kang Wang, Theodoros Foukakis, Anita Seshire, Dirk Wienke, Urban Lendahl	2024	4
3	The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer. Journal of Clinical Oncology ·Grace M. Choong, Tanya L. Hoskin, Judy C. Boughey, James N. Ingle, Matthew P. Goetz	2024	5
4	Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer npj Breast Cancer ·Roberto A. Leon‐Ferre, Jodi M. Carter, David M. Zahrieh, Jason P. Sinnwell, Roberto Salgado, Vera J. Suman, David W. Hillman, Judy C. Boughey, Krishna R. Kalari, Fergus J. Couch, James N. Ingle, Maschenka Balkenhol, Francesco Ciompi, Jeroen van der Laak, Matthew P. Goetz	2024	1
5	Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial Clinical Cancer Research ·Tufia C. Haddad, Vera J. Suman, Karthik V. Giridhar, Kostandinos Sideras, Donald W. Northfelt, Brenda Ernst, Ciara C. O’Sullivan, Ravinder J. Singh, Zeruesenay Desta, Prema P. Peethambaram, Timothy J. Hobday, Saranya Chumsri, Roberto A. Leon‐Ferre, Kathryn J. Ruddy, Siddhartha Yadav, Jodi L. Taraba, Barbara Goodnature, Matthew P. Goetz, Liewei Wang, James N. Ingle	2024	3
6	Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer Cancer Research ·Lixuan Wei, Huanyao Gao, Jia Yu, Huan Zhang, Thanh Thanh L. Nguyen, Yayun Gu, Marie R. Passow, Jodi M. Carter, Bo Qin, Judy C. Boughey, Matthew P. Goetz, Richard M. Weinshilboum, James N. Ingle, Liewei Wang	2022	17
7	Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response NAR Cancer ·Kevin J. Thompson, Roberto A. Leon‐Ferre, Jason P. Sinnwell, David Zahrieh, Vera J. Suman, Filho Otto Metzger, Sarah Asad, Daniel G. Stover, Lisa A. Carey, William M. Sikov, James N. Ingle, Minetta C. Liu, Jodi M. Carter, Eric W. Klee, Richard M. Weinshilboum, Judy C. Boughey, Liewei Wang, Fergus J. Couch, Matthew P. Goetz, Krishna R. Kalari	2022	26
8	Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial Clinical Cancer Research ·Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori J. Sokoll, Lisa A. Carey, Andres Forero-Torres, James N. Ingle, Nancy U. Lin, Rita Nanda, Anna Maria Storniolo, Suzana Tulac, Neesha Venkatesan, Natalie C. Wu, Sudhakar Marla, Scott Campbell, Michael Bates, Christopher B. Umbricht, Antonio C. Wolff, Saraswati Sukumar	2022	12
9	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer Clinical Cancer Research ·Jodi M. Carter, Mei‐Yin C. Polley, Roberto A. Leon‐Ferre, Jason P. Sinnwell, Kevin J. Thompson, Xue Wang, Yaohua Ma, David Zahrieh, Jennifer M. Kachergus, Malvika Solanki, Judy C. Boughey, Minetta C. Liu, James N. Ingle, Krishna R. Kalari, Fergus J. Couch, E. Aubrey Thompson, Matthew P. Goetz	2021	35
10	Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues Breast Cancer Research and Treatment ·John R. Hawse, Jodi M. Carter, Kirsten G. M. Aspros, Elizabeth S. Bruinsma, Justin W. Koepplin, Vivian Negron, Malayannan Subramaniam, James N. Ingle, Karen L. Rech, Matthew P. Goetz	2019	34
11	PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient JCO Clinical Cancer Informatics ·Krishna R. Kalari, Jason P. Sinnwell, Kevin J. Thompson, Xiaojia Tang, Erin E. Carlson, Jia Yu, Peter T. Vedell, James N. Ingle, Richard M. Weinshilboum, Judy C. Boughey, Liewei Wang, Matthew P. Goetz, Vera J. Suman	2018	11
12	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes npj Breast Cancer ·Duan Liu, Ming‐Fen Ho, Daniel J. Schaid, Steven E. Scherer, Krishna R. Kalari, Mohan Liu, Joanna M. Biernacka, Vivien C. Yee, Jared M. Evans, Erin E. Carlson, Matthew P. Goetz, Michiaki Kubo, D. Lawrence Wickerham, Liewei Wang, James N. Ingle, Richard M. Weinshilboum	2017	11
13	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy Cancer Research ·James N. Ingle, Fang Xie, Matthew J. Ellis, Paul E. Goss, Lois E. Shepherd, J. W. Chapman, Bingshu E. Chen, Michiaki Kubo, Yoichi Furukawa, Yukihide Momozawa, Vered Stearns, Kathleen I. Pritchard, Poulami Barman, Erin E. Carlson, Matthew P. Goetz, Richard M. Weinshilboum, Krishna R. Kalari, Liewei Wang	2016	43
14	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer Cancer Research ·Mary Jo Fackler, Zoila A. Lopez‐Bujanda, Christopher B. Umbricht, Wei Wen Teo, Soonweng Cho, Zhe Zhang, Kala Visvanathan, Stacie C. Jeter, Pedram Argani, Chenguang Wang, Jaclyn P. Lyman, Marina De Brot, James N. Ingle, Judy C. Boughey, Kandace P. McGuire, Tari A. King, Lisa A. Carey, Leslie Cope, Antonio C. Wolff, Saraswati Sukumar	2014	118
15	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Cancer Discovery ·James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura, Richard M. Weinshilboum	2013	56
16	Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Clinical Cancer Research ·Amylou C. Dueck, Monica M. Reinholz, Xochiquetzal J. Geiger, Kathleen Tenner, Karla V. Ballman, Robert B. Jenkins, Darren Riehle, Beiyun Chen, Ann E. McCullough, Nancy E. Davidson, Silvana Martino, George W. Sledge, Peter A. Kaufman, Leila A. Kutteh, Julie R. Gralow, Lyndsay N. Harris, James N. Ingle, Wilma L. Lingle, Edith A. Perez	2013	19
17	Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors Cancer Research ·Liewei Wang, Katarzyna A. Ellsworth, Irene Moon, Linda L. Pelleymounter, Bruce W. Eckloff, Yvette N. Martin, Brooke L. Fridley, Gregory D. Jenkins, Anthony Batzler, Vera J. Suman, Saranya Ravi, J. Michael Dixon, William R. Miller, Eric D. Wieben, Aman U. Buzdar, Richard M. Weinshilboum, James N. Ingle	2010	92
18	Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells Cancer Research ·Marta Santisteban, Jennifer M. Reiman, Michael K. Asiedu, Marshall D. Behrens, Aziza Nassar, Kimberly R. Kalli, Paul Haluska, James N. Ingle, Lynn C. Hartmann, Masoud H. Manjili, Derek C. Radisky, Soldano Ferrone, Keith L. Knutson	2009	320
19	Breast Cancer Risk Reduction and Membrane-Bound Catechol O -Methyltransferase Genetic Polymorphisms Cancer Research ·Yuan Ji, Janet E. Olson, Jianping Zhang, Michelle Hildebrandt, Liewei Wang, James N. Ingle, Zachary Fredericksen, Thomas A. Sellers, William H. Miller, J. Michael Dixon, Hiltrud Brauch, Michel Eichelbaum, Christina Justenhoven, Ute Hamann, Yon Ko, Thomas Brüning, Jenny Chang‐Claude, Shan Wang‐Gohrke, Daniel J. Schaid, Richard M. Weinshilboum	2008	36
20	Randomized Trial of Doxorubicin Alone or Combined with Vincristine and Mitomycin C in Women with Metastatic Breast Cancer American Journal of Clinical Oncology ·James N. Ingle, J A Mailliard, Daniel J. Schaid, James E. Krook, James B. Gerstner, D M Pfeifle, Robert F. Marschke, Hui Long, G McCormack, John Foley	1989	14

About James N. Ingle

James N. Ingle is a scholar working on Cancer Research, Oncology, Genetics, Pharmacology and Pulmonary and Respiratory Medicine, having authored 365 papers that have together received 23.6k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (146 papers), Breast Cancer Treatment Studies (129 papers), Cancer Treatment and Pharmacology (72 papers), HER2/EGFR in Cancer Research (60 papers), Advanced Breast Cancer Therapies (39 papers), Cancer Genomics and Diagnostics (25 papers), Cancer Risks and Factors (25 papers) and BRCA gene mutations in cancer (22 papers). The work is most often cited by research in Cancer Research (9.4k citations), Oncology (13.9k citations), Genetics (7.9k citations), Pharmacology (1.5k citations) and Pulmonary and Respiratory Medicine (4.0k citations). James N. Ingle has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Edith A. Perez, Silvana Martino, Vera J. Suman, Matthew P. Goetz, Nancy E. Davidson, Wilma L. Lingle, Hyman B. Muss, Dongsheng Tu, Kathleen I. Pritchard and Lois E. Shepherd. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Breast Cancer Research and Treatment, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact